- €108.73bn
- €118.75bn
- €46.44bn
- 80
- 52
- 34
- 56
Annual cashflow statement for Sanofi SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
C2019 December 31st | C2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 2,754 | 12,294 | 6,223 | 8,371 | 5,400 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | -293 | -8,001 | -105 | 20 | 272 |
| Discontinued Operations | |||||
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -419 | -325 | 1,409 | -707 | 764 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Accounts Payable | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | 7,715 | 7,418 | 10,522 | 10,526 | 10,258 |
| Capital Expenditures | -1,787 | -2,083 | -2,043 | -2,201 | -3,024 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 758 | 5,702 | -5,255 | 126 | -3,176 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -1,029 | 3,619 | -7,298 | -2,075 | -6,200 |
| Financing Cash Flow Items | -21 | -44 | -48 | -99 | -64 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -4,193 | -6,485 | -7,056 | -5,821 | -8,052 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 2,502 | 4,488 | -3,817 | 2,638 | -4,026 |